Abstract
Until recently, immunotherapy has been the only therapeutic option available for patients with advanced kidney cancer, even though different choices were often made on the two sides of the Atlantic Ocean. The absence of alternatives made different immunotherapeutic approaches common practice, even with few adequate randomized studies that addressed key questions, such as the best treatment and schedule, and so on. The recent registration of the first two, molecularly targeted, agents Sorafenib and Sunitinib could (and will) render many therapeutic approaches, e.g., single-agent Interferon, obsolete. In this review, we shall cover the past achievements obtained so far with cytokine-based immunotherapy and discuss the present role of immunotherapy in the era of molecularly targeted agents. In particular, specific indications for immunotherapy are emerging (e.g., the use of Interleukin-2 in patients with high CAIX expression), while new trials are ongoing to test immunotherapy in combination with molecularly targeted agents, such as Sorafenib, Sunitinib, or Bevacizumab.
| Original language | English |
|---|---|
| Pages (from-to) | 837-849 |
| Number of pages | 13 |
| Journal | TheScientificWorldJournal |
| Volume | 7 |
| Publication status | Published - 2007 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Environmental Science(all)
- Medicine(all)
Cite this
Cytokine-based immunotherapy for advanced kidney cancer : past results and future perspectives in the era of molecularly targeted agents. / Porta, Camillo; Paglino, Chiara; Imarisio, Ilaria; Bonomi, Lucia.
In: TheScientificWorldJournal, Vol. 7, 2007, p. 837-849.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cytokine-based immunotherapy for advanced kidney cancer
T2 - past results and future perspectives in the era of molecularly targeted agents.
AU - Porta, Camillo
AU - Paglino, Chiara
AU - Imarisio, Ilaria
AU - Bonomi, Lucia
PY - 2007
Y1 - 2007
N2 - Until recently, immunotherapy has been the only therapeutic option available for patients with advanced kidney cancer, even though different choices were often made on the two sides of the Atlantic Ocean. The absence of alternatives made different immunotherapeutic approaches common practice, even with few adequate randomized studies that addressed key questions, such as the best treatment and schedule, and so on. The recent registration of the first two, molecularly targeted, agents Sorafenib and Sunitinib could (and will) render many therapeutic approaches, e.g., single-agent Interferon, obsolete. In this review, we shall cover the past achievements obtained so far with cytokine-based immunotherapy and discuss the present role of immunotherapy in the era of molecularly targeted agents. In particular, specific indications for immunotherapy are emerging (e.g., the use of Interleukin-2 in patients with high CAIX expression), while new trials are ongoing to test immunotherapy in combination with molecularly targeted agents, such as Sorafenib, Sunitinib, or Bevacizumab.
AB - Until recently, immunotherapy has been the only therapeutic option available for patients with advanced kidney cancer, even though different choices were often made on the two sides of the Atlantic Ocean. The absence of alternatives made different immunotherapeutic approaches common practice, even with few adequate randomized studies that addressed key questions, such as the best treatment and schedule, and so on. The recent registration of the first two, molecularly targeted, agents Sorafenib and Sunitinib could (and will) render many therapeutic approaches, e.g., single-agent Interferon, obsolete. In this review, we shall cover the past achievements obtained so far with cytokine-based immunotherapy and discuss the present role of immunotherapy in the era of molecularly targeted agents. In particular, specific indications for immunotherapy are emerging (e.g., the use of Interleukin-2 in patients with high CAIX expression), while new trials are ongoing to test immunotherapy in combination with molecularly targeted agents, such as Sorafenib, Sunitinib, or Bevacizumab.
UR - http://www.scopus.com/inward/record.url?scp=34548052428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548052428&partnerID=8YFLogxK
M3 - Article
C2 - 17619768
AN - SCOPUS:34548052428
VL - 7
SP - 837
EP - 849
JO - The Scientific World Journal
JF - The Scientific World Journal
SN - 2356-6140
ER -